Trials / Completed
CompletedNCT02967354
[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes
[11C]5-Hydroxy-tryptophan Positron Emission Tomography for Assessment of Islet Mass During Progression of Type 2 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Per-Ola Carlsson · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
Cross-sectional study to investigate subjects at different stages of type 2 diabetes development with expected stratification of pancreatic islet mass. Non-diabetic individuals were assigned as control. The primary outcome was the \[11C\]5-hydroxy-tryptophan uptake and retention in the pancreas as a surrogate marker for the endogenous islet mass.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan | Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2016-11-18
- Last updated
- 2018-01-30
- Results posted
- 2017-11-29
Source: ClinicalTrials.gov record NCT02967354. Inclusion in this directory is not an endorsement.